bioAffinity prices $4M private placement to fund cancer diagnostics push
What's the deal? bioAffinity Technologies has priced a $4 million private placement, selling roughly 8.46 million shares of common stock — or pre-funded warrants in lieu — to a single institutional investor. The Nasdaq-listed biotechnology company focuses on noninvasive diagnostics and early cancer detection.
The terms: The combined price is $0.4727 per share and accompanying warrants, priced at-the-market under Nasdaq rules. The deal includes two warrants to buy up to 16,924,054 shares, exercisable after stockholder approval and expiring five years from issuance.
Who's involved? WallachBeth CapitalDealroom has a profile for this one. Try Dealroom → is the sole placement agent. Gross proceeds are estimated at about $4 million before fees and expenses, with the offering expected to close on or about August 14, 2026, subject to customary conditions.
The fine print: The securities are being sold under a private placement exemption and have not been registered under the Securities Act. bioAffinity said it will provide customary registration rights for the shares underlying the warrants.
The signal: At-the-market pricing and heavy warrant coverage point to a small-cap biotech raising capital on tight terms. For a company building noninvasive cancer tests, the modest $4 million infusion buys runway rather than scale.
Read more: wallstreet-online.de
Image credit: Generated with Gemini
